Cargando…

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer

PURPOSE: To evaluate the prognostic value of prostate-specific antigen nadir (nPSA) after high-dose-rate (HDR) brachytherapy in clinically non-metastatic high-risk prostate cancer patients. MATERIAL AND METHODS: Data from 216 patients with high-risk or locally advanced prostate cancer who underwent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsumura, Hideyasu, Satoh, Takefumi, Ishiyama, Hiromichi, Tabata, Ken-ichi, Komori, Shouko, Sekiguchi, Akane, Ikeda, Masaomi, Kurosaka, Shinji, Fujita, Tetsuo, Kitano, Masashi, Hayakawa, Kazushige, Iwamura, Masatsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2016
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873555/ https://www.ncbi.nlm.nih.gov/pubmed/27257412 http://dx.doi.org/10.5114/jcb.2016.59686

Ejemplares similares

Catheter displacement prior to the delivery of high-dose-rate brachytherapy in the treatment of prostate cancer patients
por: Kawakami, Shogo, et al.
Publicado: (2014)

Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2017)

High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up
por: Ishiyama, Hiromichi, et al.
Publicado: (2014)

Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy
por: Kawakami, Shogo, et al.
Publicado: (2017)

(125)Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up
por: Sekiguchi, Akane, et al.
Publicado: (2014)

Comparison of three different techniques of low-dose-rate seed implantation for prostate cancer
por: Ishiyama, Hiromichi, et al.
Publicado: (2015)

A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial
por: Ishiyama, Hiromichi, et al.
Publicado: (2018)

Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS
por: Ishiyama, Hiromichi, et al.
Publicado: (2016)

A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
por: Kainuma, Takuro, et al.
Publicado: (2019)

Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
por: Tabata, Ken-ichi, et al.
Publicado: (2012)

Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients
por: Fujii, Kyohei, et al.
Publicado: (2023)

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2022)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer
por: Yanagisawa, Nobuyuki, et al.
Publicado: (2021)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
por: Kawakami, S., et al.
Publicado: (2022)

Assessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy?
por: Soda, Itaru, et al.
Publicado: (2015)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Imaging Cherenkov emission for quality assurance of high-dose-rate brachytherapy
por: Yogo, Katsunori, et al.
Publicado: (2020)

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

A novel prognostic model for Japanese patients with newly diagnosed bone‐metastatic hormone‐naïve prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study
por: Kawahara, Takashi, et al.
Publicado: (2020)

Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
por: Ishiyama, Hiromichi, et al.
Publicado: (2021)

Clinical Implications of Nadir Serum Prostate-Specific Antigen Levels After Transurethral Enucleation of the Prostate
por: Cheng, Yung-Ting, et al.
Publicado: (2022)

Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus ‘X’
por: Ahmed, Kamran A, et al.
Publicado: (2014)

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2021)

Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer
por: Mori, Kohei, et al.
Publicado: (2023)

Impact of perioperative factors on nadir serum prostate‐specific antigen levels after holmium laser enucleation of prostate
por: Martos, Mary, et al.
Publicado: (2021)

Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy
por: Ishiyama, Hiromichi, et al.
Publicado: (2016)

Prostate‐specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low‐dose‐rate brachytherapy or external beam radiotherapy for localized prostate cancer
por: Nishimura, Shuichi, et al.
Publicado: (2018)

HDR Brachytherapy in the Management of High-Risk Prostate Cancer
por: Masson, Susan, et al.
Publicado: (2012)

High dose-rate brachytherapy in the treatment of prostate cancer
por: Mendez, Lucas C., et al.
Publicado: (2018)

Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2021)

Complete biochemical response following metastasis-directed radiotherapy for oligometastatic prostate cancer: A case report
por: Okuda, Satoshi, et al.
Publicado: (2020)

Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer
por: Inoue, Yusuke, et al.
Publicado: (2014)

Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”
por: Masson, Susan, et al.
Publicado: (2016)

Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA
por: Barra, Salvina, et al.
Publicado: (2014)

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir
por: Anwar, Mekhail, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4nuqdrdu4qdsul1gn8fi6qe71i